Home / Stocks / 3b Blackbio Dx Ltd.
3BBLACKBIO

3b Blackbio Dx Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,316.6

Change

-5.0 (-0.38%)

Open

₹1,319.9

Prev. Close

₹1,321.6

Day High

₹1,345.9

Day Low

₹1,300.2

Volume Analysis

Traded

7,132

Delivered

3,873

Delivery %

54.3%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (36.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (25.5%)
  • •Strong 3-year revenue growth (31.8%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,387.3 ₹1,366.6 ₹1,341.6 ₹1,320.9 ₹1,295.9 ₹1,275.2 ₹1,250.2
Fibonacci ₹1,366.6 ₹1,349.14 ₹1,338.36 ₹1,320.9 ₹1,303.44 ₹1,292.66 ₹1,275.2
Camarilla ₹1,329.17 ₹1,324.98 ₹1,320.79 ₹1,320.9 ₹1,312.41 ₹1,308.22 ₹1,304.03

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+1.02%

1 Month

-0.17%

3 Months

+9.49%

6 Months

+9.16%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹788.74

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

14.26%

Net margin 35.12% × asset turnover 0.35x × equity multiplier 1.16x

Company Overview

Sector

Healthcare

Market Cap

₹1,157 Cr

P/E (TTM)

19.7

ROE

19.8%

Book Value

₹405.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

3b Blackbio Dx Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Liquidity (18/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (36.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

64/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

50

Valuation

51

Cash Flow

59

Corporate Governance

78

Momentum

40

Institutional Ownership

33

Business Quality

95

Risk & Volatility

55

Liquidity

18

From Screener.in

  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • +Company's median sales growth is 21.9% of last 10 years
  • −Earnings include an other income of Rs.26.6 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 19 18 23 19 29 25 22 22 34 50 35 33 48
Expenses + 11 9 13 8 13 10 15 10 19 29 27 25 27
Operating Profit 8 9 10 11 16 15 8 12 15 22 8 9 21
OPM % 41.0% 50.0% 43.0% 56.0% 55.0% 59.0% 35.0% 53.0% 43.0% 43.0% 24.0% 25.0% 44.0%
Other Income + 3 3 4 4 3 3 5 4 6 6 10 6 5
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 1 0 4 1 1
Profit before tax 10 11 14 14 19 18 13 16 20 27 15 13 24
Tax % 26.0% 24.0% 36.0% 21.0% 23.0% 24.0% 36.0% 20.0% 23.0% 16.0% 33.0% 32.0% 26.0%
Net Profit + 8 9 9 11 15 13 8 13 15 22 10 9 18
EPS in Rs 10 10 10 13 17 16 10 15 17 25 11 11 21
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 20 27 36 52 44 -2 14 16 98 57 51 42

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 19 17 16 23 23 29 227 81 62 74 96 142 168
Expenses + 18 16 14 18 16 20 77 44 33 41 46 85 108
Operating Profit 1 2 3 5 7 9 150 37 29 33 50 57 60
OPM % 7.0% 9.0% 16.0% 23.0% 31.0% 32.0% 66.0% 46.0% 47.0% 44.0% 52.0% 40.0% 36.0%
Other Income + 0 0 0 0 1 2 3 7 7 13 15 26 27
Interest 1 1 1 1 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 1 1 1 1 1 1 1 5 7
Profit before tax 0 0 1 5 7 10 152 43 35 44 64 77 79
Tax % 23.0% 23.0% 19.0% 24.0% 25.0% 23.0% 25.0% 26.0% 27.0% 28.0% 25.0% 22.0% —
Net Profit + 0 0 1 3 5 8 114 32 26 32 48 60 59
EPS in Rs 0 1 2 5 8 10 152 43 35 37 56 68 68
Dividend Payout % 0.0% 0.0% 17.0% 9.0% 6.0% 7.0% 6.0% 24.0% 8.0% 8.0% 7.0% 7.0% —
Sales growth -14 -8 -7 44 0 24 685 -64 -23 20 30 47 61

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 4 4 5 12 16 25 125 146 185 214 260 316 339
Borrowings + 8 8 9 6 6 4 2 3 2 1 0 3 3
Other Liabilities + 7 6 6 6 8 9 59 37 19 24 27 51 52
Total Liabilities 25 24 26 30 36 45 194 192 214 248 296 378 402
Fixed Assets + 4 3 3 4 4 4 5 7 8 7 7 28 26
CWIP 0 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 1 59 93 92 117 156 158 169
Other Assets + 21 21 22 26 32 40 130 93 114 123 132 193 208
Total Assets 25 24 26 30 36 45 194 192 214 248 296 378 402
Equity Capital 6 6 6 6 6 7 7 7 9 9 9 9 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 1 1 2 4 7 98 37 20 27 43 52
Cash from Investing Activity + 0 0 0 -1 -1 -1 -70 -28 15 -20 -33 -24
Cash from Financing Activity + 0 -1 0 0 -1 1 -2 -15 -5 -4 -3 -1
Net Cash Flow 0 0 0 1 2 7 26 -6 30 3 7 28
Free Cash Flow 0 1 0 1 3 6 96 35 18 26 42 27
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 23 69 36 52 71 101 90 129 100 115 116 121

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 38.43% → 40.95%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 56.99% 53.85% 53.48% 53.48% 54.29% 54.64% 54.28% 54.26% 54.27% 54.5% 54.4% 54.26%
Promoters 38.43% 41.29% 41.28% 41.28% 41.28% 41.28% 41.28% 41.28% 41.27% 40.94% 40.95% 40.95%
FII 3.38% 2.97% 3.28% 3.27% 2.68% 2.49% 2.7% 2.64% 2.57% 2.57% 2.5% 2.46%
DII 1.18% 1.89% 1.96% 1.96% 1.74% 1.6% 1.76% 1.82% 1.87% 1.98% 2.15% 2.33%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
3b Blackbio Dx Ltd. (this stock) 1,157 19.7 3.33 19.8%
Gpt Healthcare Limited 1,136 27.3 — 28.5%
Bafna Pharmaceuticals Ltd 1,121 — 2.19 -6.18%
Sigachi Industries Ltd 1,088 41.3 2.02 5.78%
Laxmi Dental Limited 1,076 29.7 4.05 14.8%
Gujarat Kidney N Sup Sp L 1,269 66.8 4.82 11.1%
Kopran Ltd 1,281 32.6 2.44 4.91%

Which Mutual Funds Hold 3b Blackbio Dx Ltd.?

Frequently Asked Questions about 3b Blackbio Dx Ltd.

Community Sentiment

What are other investors saying about 3b Blackbio Dx Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.